Premium
TGF‐β1 content in atherosclerotic plaques, TGF‐β1 serum concentrations and incident coronary events
Author(s) -
Herder Christian,
Peeters Wouter,
Zierer Astrid,
de Kleijn Dominique P. V.,
Moll Frans L.,
Karakas Mahir,
Roden Michael,
Meisinger Christa,
Thorand Barbara,
Pasterkamp Gerard,
Koenig Wolfgang
Publication year - 2012
Publication title -
european journal of clinical investigation
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.164
H-Index - 107
eISSN - 1365-2362
pISSN - 0014-2972
DOI - 10.1111/j.1365-2362.2011.02587.x
Subject(s) - medicine , hazard ratio , prospective cohort study , proportional hazards model , body mass index , cohort , cardiology , population , coronary atherosclerosis , transforming growth factor , gastroenterology , coronary artery disease , confidence interval , environmental health
Eur J Clin Invest 2012; 42 (3): 329–337 Abstract Background We tested the hypothesis that high TGF‐β1 content in atherosclerotic plaques and high TGF‐β1 serum levels are associated with lower risk of coronary events in two independent prospective studies. Materials and methods In the prospective Athero‐Express biobank study, total TGF‐β1 plaque levels were measured in 632 atherosclerotic lesions from patients who underwent carotid endarterectomy. In a population‐based case‐cohort study within the Monitoring of trends and determinants in cardiovascular disease (MONICA)/Cooperative Health Research in the Region of Augsburg (KORA) Augsburg studies, baseline total TGF‐β1 serum levels were measured in 333 individuals with and 1728 without incident coronary events. Results Patients with TGF‐β1 content in their plaques above the study median did not have a lower risk of coronary events than patients with lower TGF‐β1 levels [adjusted HR (95% CI) 1·46 (0·83–2·53); P = 0·16; mean follow‐up 2·6 ± 0·7 years] in the Athero‐Express biobank study. Cox proportional hazard models adjusting for age, sex, body mass index, metabolic factors, lifestyle factors and survey did not reveal a significant association between TGF‐β1 serum levels and incident coronary events [HR (95% CI) for increasing TGF‐β1 tertiles 1·0, 1·22 (0·88–1·68), 1·13 (0·82–1·57); P = 0·47; mean follow‐up: 10·8 ± 4·6 years] in the MONICA/KORA Augsburg studies. Conclusion Our results indicate that high TGF‐β1 content in human atherosclerotic plaques and high serum levels of TGF‐β1 are not associated with reduced risk of coronary events.